Trends of average and best race times for IRONMAN^® age group triathletes. حسب Beat Knechtle (5504402)

الموضوعات:

S2 Data - حسب Beat Knechtle (5504402)

الموضوعات:

Number of finishers by sex and men-to-women ratio over the years between 2002 and 2022. حسب Beat Knechtle (5504402)

الموضوعات:

Split and overall IRONMAN^® race times histograms for women and men. حسب Beat Knechtle (5504402)

الموضوعات:

Men-to-women ratio across age groups. حسب Beat Knechtle (5504402)

الموضوعات:

Trend of the sex difference across years in overall race time. حسب Beat Knechtle (5504402)

الموضوعات:

Lipid layer thickness distribution in the inferior half of cornea (nm). حسب Yongwoo Lee (2265172)

الموضوعات:

Flowchart of overall study protocol. حسب Yongwoo Lee (2265172)

الموضوعات:

Changes in symptom scores and signs of dry eye disease and meibomian gland dysfunction after treatment with intensive pulse light and meibomian gland expression (n =  218). حسب Yongwoo Lee (2265172)

الموضوعات:

Change in the vertical distribution of the lipid layer thickness after intensive pulse light treatment (IPL; nm) combined with meibomian gland expression (MGX). حسب Yongwoo Lee (2265172)

الموضوعات:

Patient demographics. حسب Yongwoo Lee (2265172)

الموضوعات:

The catalase enzyme response of <i>A</i>. <i>albopictus</i> larvae decreased (1.5-fold) in response to <i>M</i>. <i>robertsii</i>-derived copper nanoparticles. حسب Perumal Vivekanandhan (4863484)

Receiver operating characteristic curve for anti-NIE antibodies for <i>S. stercoralis.</i> حسب Jannet A. Tobon Ramos (20855642)

"…The seroprevalence did not significantly decrease following DA treatment. These results include all individuals sampled, irrespective of whether they took the medications. …"

Between the PCSO-524 group and the placebo group unpaired comparisons of the change between visits of quality of life and respiratory variables scores. حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

A flow diagram outlining the number of dogs in each group during the study (visit 1 = day 0, visit 2 = day 35, and visit 3 = day 70). حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

Distribution of quality of life and respiratory variables scores of all 3 visits (visit = day 0, visit 2 = day 35, and visit 3 = day 70) of the PCSO-524 group and the placebo group... حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

The baseline characteristics of classifications and body condition score of the 2 groups (frequencies) at entry (visit 1, day 0). حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

Tricuspid regurgitation pressure gradient of all 17 dogs. حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

Tricuspid regurgitation pressure gradient in the PCSO-524 and placebo groups. حسب Nattapon Riengvirodkij (11268720)

الموضوعات:

Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. حسب Haiyang Dong (4783608)